![Sina Bavari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sina Bavari
Corporate Officer/Principal bei TONIX PHARMACEUTICALS HOLDING CORP.
Aktive Positionen von Sina Bavari
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TONIX PHARMACEUTICALS HOLDING CORP. | Corporate Officer/Principal | 25.07.2022 | - |
Healion Bio, Inc.
![]() Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Direktor/Vorstandsmitglied | - | - |
Technik-/Wissenschafts-/F&E-Leiter | - | - | |
Gründer | - | - |
Karriereverlauf von Sina Bavari
Ehemalige bekannte Positionen von Sina Bavari
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
U.S. Army Medical Research Institute for Infectious Diseases | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Sina Bavari
University of Southern California | Graduate Degree |
University of Nebraska Medical Center | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Founder | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TONIX PHARMACEUTICALS HOLDING CORP. | Health Technology |
Private Unternehmen | 1 |
---|---|
Healion Bio, Inc.
![]() Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Health Technology |
- Börse
- Insiders
- Sina Bavari
- Erfahrung